Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1982 2
1983 1
1984 1
1986 3
1987 3
1988 2
1989 2
1990 3
1991 6
1992 3
1993 8
1994 2
1995 6
1996 12
1997 6
1998 5
1999 13
2000 9
2001 6
2002 8
2003 4
2004 9
2005 12
2006 14
2007 18
2008 16
2009 10
2010 15
2011 18
2012 14
2013 11
2014 22
2015 30
2016 24
2017 32
2018 38
2019 51
2020 55
2021 62
2022 72
2023 91
2024 40

Text availability

Article attribute

Article type

Publication date

Search Results

691 results

Results by year

Filters applied: . Clear all
Page 1
Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.
Ji S, Feng L, Fu Z, Wu G, Wu Y, Lin Y, Lu D, Song Y, Cui P, Yang Z, Sang C, Song G, Cai S, Li Y, Lin H, Zhang S, Wang X, Qiu S, Zhang X, Hua G, Li J, Zhou J, Dai Z, Wang X, Ding L, Wang P, Gao D, Zhang B, Rodriguez H, Fan J, Clevers H, Zhou H, Sun Y, Gao Q. Ji S, et al. Sci Transl Med. 2023 Jul 26;15(706):eadg3358. doi: 10.1126/scitranslmed.adg3358. Epub 2023 Jul 26. Sci Transl Med. 2023. PMID: 37494474 Free PMC article.
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, Lin J, Zhang J, Zhu W, Jia H, Qin L, Lu L, Chen J. Yi C, et al. Hepatology. 2021 Nov;74(5):2544-2560. doi: 10.1002/hep.31921. Epub 2021 Aug 25. Hepatology. 2021. PMID: 34036623
Consistently, in C57BL/6 wild-type mice receiving anti-programmed cell death 1 (PD-1) therapy, PD-L1 expression and Treg infiltration in s.c. tumors were reduced when adding lenvatinib to the scheme. ...
Consistently, in C57BL/6 wild-type mice receiving anti-programmed cell death 1 (PD-1) therapy, PD-L1 expression and Treg infiltration in …
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.
Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, Graham NMH, Liu N, Paccaly A, Wu R, Spindler A. Emery P, et al. Rheumatology (Oxford). 2019 May 1;58(5):849-858. doi: 10.1093/rheumatology/key361. Rheumatology (Oxford). 2019. PMID: 30590833 Free PMC article. Clinical Trial.
METHODS: In ASCERTAIN, patients were randomized 1: 1: 2 to 24 weeks' double-blind sarilumab 150 or 200 mg every 2 weeks s.c. or tocilizumab 4 mg/kg every 4 weeks i.v., increased to 8 mg/kg if clinically indicated. In Study 1309, patients were randomized 1: 1: 1: 1 t …
METHODS: In ASCERTAIN, patients were randomized 1: 1: 2 to 24 weeks' double-blind sarilumab 150 or 200 mg every 2 weeks s.c. o …
Case 296.
Lu CY, Tseng PC, Chen KC, Huang CC, Tsang YM, Lee TH, Lin CK, Chung CS. Lu CY, et al. Radiology. 2021 Aug;300(2):481-483. doi: 10.1148/radiol.2021201790. Radiology. 2021. PMID: 34310227
Rational design of a Fe/S/N/C catalyst from ZIF-8 for efficient oxygen reduction reaction.
Chen D, Fang Z, Ma X, Li Z, Lin H, Ying W, Peng X. Chen D, et al. Nanotechnology. 2020 Nov 20;31(47):475404. doi: 10.1088/1361-6528/abaf84. Nanotechnology. 2020. PMID: 32886645
After further pyrolysis, the Fe/S/N/C catalyst was obtained with uniformly dispersed Fe-N(x), C-S-C active sites and high specific surface area. The Fe/S/N/C catalyst shows a high half-wave potential in alkaline medium, nearly 32 mV higher than the commercial Pt/C, …
After further pyrolysis, the Fe/S/N/C catalyst was obtained with uniformly dispersed Fe-N(x), C-S-C active sites and high spec …
TBAJ-876 Retains Bedaquiline's Activity against Subunits c and ε of Mycobacterium tuberculosis F-ATP Synthase.
Sarathy JP, Ragunathan P, Shin J, Cooper CB, Upton AM, Grüber G, Dick T. Sarathy JP, et al. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e01191-19. doi: 10.1128/AAC.01191-19. Print 2019 Oct. Antimicrob Agents Chemother. 2019. PMID: 31358589 Free PMC article.
The developmental compound inhibits the mycobacterial F-ATP synthase via a dual-subunit mechanism of interfering with the functions of both the enzyme's c and epsilon subunits....
The developmental compound inhibits the mycobacterial F-ATP synthase via a dual-subunit mechanism of interfering with the functions of both …
Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline.
Sarathy JP, Gruber G, Dick T. Sarathy JP, et al. Antibiotics (Basel). 2019 Dec 11;8(4):261. doi: 10.3390/antibiotics8040261. Antibiotics (Basel). 2019. PMID: 31835707 Free PMC article. Review.
Two mechanisms of action of BDQ are broadly accepted. A direct mechanism involves BDQ binding to the enzyme's c-ring to block its rotation, thus inhibiting ATP synthesis in the enzyme's catalytic alpha(3)beta(3)-headpiece. ...
Two mechanisms of action of BDQ are broadly accepted. A direct mechanism involves BDQ binding to the enzyme's c-ring to block …
691 results